EUCTR2007-001746-40-HU进行中（未招募）不适用
A Phase IIb study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of ARX201 Following Repeated Dosing to Young Adult Patients with Childhood Onset Growth Hormone Deficiency (GHD)
Ambrx, Inc., USA0 个研究点目标入组 45 人开始时间: 2007年4月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Young adults, male or female, age 18 to 30 years, with growth
- •hormone deficiency of childhood onset whom have completed growth
- •(and in the investigators opinion have achieved their final height);
- •2. hGH level below the predetermined cut-off value in one of the dynamic
- •endocrine testing (If there are more than two tests performed all should
- •have peak hGH levels below predetermined cut-off values):
- •a. If Insulin Tolerance Test, the peak hGH value must be below 3
- •b. If Arginine-GHRH Test, the peak hGH value must be below 5
- •ng/ml. This test is however not acceptable in patients with
- •GHD of hypothalamic origin (e.g. patients having received
- •irradiation of the hypothalamic-pituitary region);
- •c. If Arginine Test alone, the GH peak must be below 1.4 ng/ml.
- •This test is acceptable only in patients in which Insulin
- •Tolerance Test is contraindicated and are suffering from GHD
- •of hypothalamic origin;
- •d. Patients without results of any dynamic endocrine testing
- •having at least 3 other pituitary hormone deficiencies;
- •3. Screening IGF-I level of = - 2 SDS standardised for age and sex
- •according to the central laboratory reference values;
- •4. rhGH treatment naïve or stopped this treatment for at least 6 months
- •prior to study entry ;
- •5. Receiving replacement therapies for any other hypothalamic-pituitary
- •axes deficiencies for at least 3 months prior to study entry; (For
- •patients receiving estrogen, ONLY transdermal application is
- •acceptable. Temporary adjustment of glucocorticoid replacement
- •therapy, as appropriate, is acceptable)
- •6. Confirmed to be negative for anti-hGH antibodies;
- •7. Females must not intend to conceive during or shortly after the study.
- •They must be either post-menopausal, surgically incapable of bearing
- •children, or practicing an acceptable method of birth control (e.g.,
- •intrauterine device or spermicide and barrier but NOT hormonal
- •contraceptives) and be willing to continue the same method of birth
- •control during and for 30 days after the last dose of study medication.
- •Oral contraceptives must be discontinued at least 14 days prior to
- •receipt of the first dose of study drug and are not permitted during the
- •study. Females of child-bearing potential must have a negative serum
- •pregnancy test at screening and a negative urine pregnancy test before
- •the first dose of study drug;
- •8. Have negative drugs of abuse screen at Screening and on Day -1 of
- •9. Willing and able to give informed consent; and
- •10. Willing and able to undergo procedures required by this protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Evidence of growth of pituitary adenoma or other intracranial tumor
- •within the last 12 months which has to be confirmed by computer
- •tomography (CT) or magnetic resonance imaging (MRI) scan (with
- •contrast) within 3 months prior to study entry. Patients with primary
- •growth hormone deficiency are exempt from this requirement
- •2. History of malignancy other than I) cranial tumor or leukemia causing
- •GHD or II) fully treated basal cell carcinoma;
- •3. Subjects presenting with any clinically significant ECG abnormality,
- •including a corrected QT interval (QTc) > 450 msec for males or a
- •corrected QT interval (QTc) > 470 msec for females using Bazett’s
- •4. Evidence of active malignancy or concurrent anti-tumor therapy;
- •5. Evidence of intracranial hypertension;
- •6. Significant hepatic dysfunction (persistent elevation of alanine
- •transaminase [ALT] or aspartate transaminase [AST] >1.5 x upper limit
- •of normal);
- •7. Significant renal impairment as indicated by serum creatinine levels
- •above the normalized range for age;
- •8. Any other major medical conditions, including e.g., clinically manifest
- •diabetes mellitus, hypertension, tuberculosis, major surgery within the
- •last three months, or significantly abnormal laboratory tests (e.g.,
- •disturbed calcium homeostasis); or any other conditions (e.g., acute
- •infections) that may influence drug absorption, metabolism or excretion
- •or that may interfere with any study variables in the judgment of the
- •investigator;
- •9. Inadequate T4 or adrenocorticoid replacement;
- •10. Positive results from serology examination for HBV, HCV or HIV;
- •11. History of alcohol or drug abuse as specified by the Diagnostic and
- •Statistical Manual of Mental Disorders, 4th edition (DSM-IV) in the year
- •before screening;
- •12. Hypersensitivity to the study treatment;
- •13. Systemic corticosteroids other than in replacement doses within the 3
- •months before study entry. (Temporary adjustment of glucocorticoids,
- •as appropriate, is acceptable);
- •14. Anabolic steroids other than gonadal steroid replacement therapy
- •within 2 months before study entry;
- •15. History of non-compliance with medications, un-cooperativeness or
- •drug abuse;
- •16. Blood donation or any major blood loss >500 mL within the past 90
- •days prior to study entry;
- •17. History of any medical or psychiatric condition that in the opinion of the
- •investigator would pose a risk for participation in this study or interfere
- •with the compliance needed for this study;
- •18. Females who are pregnant or breast-feeding;
- •19. History of poor compliance with other chronic therapy; and
- •20. Participation in any other trial of an investigational agent within 90 days
- •prior to screening.
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe HypoglycemiaType 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Severe HypoglycemiaMedDRA version: 20.0Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 21.1Level: LLTClassification code 10081605Term: Severe hypoglycemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2022-002292-11-DEVertex Pharmaceuticals Incorporated37
进行中（未招募）
不适用
A Phase 1/2 of Peptide Vaccine S-488210 in Patients with Head and Neck Squamous Cell CarcinomaEUCTR2011-005014-12-DEShionogi & Co., Ltd.92
招募中
2 期
A Safety, Tolerability, and Efficacy Study of VX-264 in Subjects With Type 1 DiabetesType 1 Diabetes Mellitus2024-515583-32-00Vertex Pharmaceuticals Inc., Vertex Pharmaceuticals Inc.4
招募中
3 期
A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX- 880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia2024-513929-23-00Vertex Pharmaceuticals Inc.16
进行中（未招募）
1 期
A clinical study to evaluate the safety, tolerability, and efficacy of INCB001158 in combination with chemotherapy in subjects with advanced or metastatic solid tumors.EUCTR2017-002904-29-GBIncyte Corporation249